EORTC 2018 – Establishment of ImmunoGraft® with human immune system(HIS) and PDX co-engraftment using NOG-EXL mice to evaluate checkpoint inhibitors

Title

Establishment of ImmunoGraft® with human immune system(HIS) and PDX co-engraftment using NOG-EXL mice to evaluate checkpoint inhibitors

Authors

Bhavna Verma1, Maria Mancini1, Angela Davies1, David Sidransky2, Amy Wesa1 and Neal Goodwin1
1 Champions Oncology, USA. 2 Johns Hopkins University School of Medicine, USA.

Abstract

The clinical success of immune checkpoint modulators and development of next-generation immune-oncology (IO) agents underscores the need for robust patient-derived models to evaluate novel therapeutics. The Champions ImmunoGraft® model utilizing humanized NOG mice is an innovative pre-clinical model for assess the efficacy of IO agents against solid tumors. Improved immunodeficient mouse strains, such as triple transgenic NOG-EXL mice expressing huIL-3 and huGM-CSF, allows for superior HIS development. In this study we compared human immune lineage development, tumor infiltrating lymphocytes, as well as an assessment of tumor response to checkpoint inhibitors in this humanized mouse platform.